GILD · Company research
8 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Gilead Sciences expects to report results from its Phase 3 study of Trodelvy (sacituzumab govitecan) for Advanced or recurrent endometrial cancer in the second half of 2026 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead Sciences expects to report results from its Phase 2 study of Emvistagrast (GS-1427); edecesertib for Inflammatory bowel disease; cutaneous lupus erythematosus in the second half of 2026 (no exact date yet). Phase 2 is the stage that tests whether the drug actually works.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead Sciences expects to report results from its Phase 1 study of GS-3242 injection for HIV treatment (long-acting) in the second half of 2026 (no exact date yet). Phase 1 is an early safety study in a small group of people.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is due to decide by Dec 23, 2026 whether to approve Gilead Sciences’ anitocabtagene autoleucel (anito-cel) for Fourth-line+ relapsed/refractory multiple myeloma. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is due to decide by Feb 2, 2027 whether to approve Gilead Sciences’ Yeztugo (lenacapavir) 300-mg once-weekly oral tablets for HIV pre-exposure prophylaxis (PrEP). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Islatravir/lenacapavir once-weekly oral HIV regimen filings and potential launch, expected during 2027 (no exact date yet). A company milestone for Gilead Sciences (Islatravir + lenacapavir (ISL/LEN, with Merck) for HIV-1 treatment, virologically suppressed): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Anito-cel potential filing in second-line multiple myeloma (iMMagine-3), expected during 2027 (no exact date yet). A company milestone for Gilead Sciences (Anito-cel (anitocabtagene autoleucel) for Relapsed/refractory multiple myeloma, 2L): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead Sciences expects to report results from its Phase 3 study of Lenacapavir once-yearly IM for HIV pre-exposure prophylaxis during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Gilead Sciences’ Bictegravir 75 mg / lenacapavir 50 mg (BIC/LEN) for HIV-1 treatment in virologically suppressed adults was due on Aug 27, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Gilead Sciences’ Trodelvy (sacituzumab govitecan-hziy) for First-line metastatic triple-negative breast cancer on Jun 24, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Gilead Sciences’ Yeztugo (lenacapavir) 300-mg tablet for HIV pre-exposure prophylaxis on Jun 15, 2026. That clears it for sale in the US.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Gilead Sciences reported results from its Phase 3 study of Islatravir/lenacapavir (ISL/LEN) for HIV-1 treatment in virologically suppressed adults on Jun 8, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Gilead Sciences’ Hepcludex (bulevirtide-gmod) for Chronic hepatitis delta virus infection on May 22, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Gilead Sciences’ Bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) for HIV-1 in virologically suppressed adults on Apr 29, 2026. That clears it for sale in the US.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to GILD.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.